DriveNews.co.uk: Your Ultimate Hub for Comprehensive Automotive News and Insights! We bring you the latest reports, stories, and updates from the world of cars, covering everything from vehicle launches to driving tips. Stay with DriveNews.co.uk to stay revved up about the automotive world 24/7

Contacts

  • Owner: SNOWLAND s.r.o.
  • Registration certificate 06691200
  • 16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
  • Czech Republic

This Woman Will Decide Which Babies Are Born

God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born with a severe intellectual disability. Or go blind. Or become obese. A regular baby might not even make it to childbirth. Any of those things could still happen to an Orchid baby, yes, but the risk, says 29-year-old Noor Siddiqui, plummets if you choose her method. It’s often called “genetic enhancement.”

Whenever I bring up Orchid in polite company, people squirm. “I’m uncomfortable,” they say. “Not for me.” “So unnatural.” Inevitably, Nazis get mentioned, as does a related word that starts with “eu” and ends in “genics.” (Orchid prefers I not utter it.) One new mom I was talking to was particularly, headshakingly disturbed. Then, a few minutes later, in an attempt to change the subject, she announced to the room that she’d just fed her 6-month-old his first peanut, and that in three months’ time she’d be feeding him his first shrimp, because that’s what the science says she must do to protect him from developing allergies.

Which is, of course, the entirety of Siddiqui’s pitch: to—based on what the science says—protect future people from future suffering. It’s why, as a teenage Thiel Fellow, Siddiqui launched a medical startup; and why, at 25, she started Orchid. It’s also why, now that the company’s gene-enhancing product is available, she wanted to be one of its first customers.

Siddiqui and her husband are perfectly fertile, but for this kind of intervention to work, you need embryos. So in 2022, Siddiqui underwent IVF at Stanford, wound up with 16 contenders, and sent off representative slivers to Orchid’s lab in North Carolina. Typically, preimplantation testing scans only for alarming abnormalities, and then a doctor selects the nicest looker. This is not that. This is something that, as Siddiqui tells me, “has been on society’s mind—sci-fi’s mind—for a generation”: a first-of-its-kind picture of every baby-to-be’s genetic destiny. Right now, Orchid calculates each embryo’s likelihood of one day suffering from any number of the more

Read more on wired.com